Cedars-Sinai Study Rocks 650,000 IBS Patients

Person holding their stomach with a graphic of intestines overlayed

Everyday IBS pills you trust could silently double your risk of death over decades—what if your relief is costing you years?

Story Snapshot

Cedars-Sinai study tracks 650,000+ IBS patients over nearly 20 years, largest of its kind.
Antidepressants link to 35% higher mortality; loperamide and diphenoxylate double the risk.
FDA-approved IBS drugs and antispasmodics show no increased death risk.
Associations may stem from complications like heart events and falls, not direct causation.
Dr. Ali Rezaie urges patients to weigh small but real long-term risks with doctors.

Study Reveals Hidden Dangers in Common IBS Treatments

Cedars-Sinai researchers analyzed electronic health records from over 650,000 U.S. adults with IBS spanning nearly two decades. They examined treatments including FDA-approved IBS drugs, antidepressants, antispasmodics, and opioid-based antidiarrheals like loperamide and diphenoxylate. Long-term antidepressant use correlated with 35% higher mortality risk, with users facing 1.6% death rate versus 1.01% for non-users. Tricyclic antidepressants and SSRIs showed 27-32% increases, while mirtazapine linked to higher rates potentially due to confounding factors.

Opioid antidiarrheals doubled death risks: diphenoxylate users had 2.34% mortality versus 1.38% in non-users; loperamide showed 2.1% versus 0.98%. These drugs target IBS with diarrhea (IBS-D) symptoms. Findings held across subgroups including IBS-D (50% higher antidepressant risk) and IBS-C (56% higher), plus consistencies in sex, age, BMI, and ethnicity. FDA-approved IBS medications, antispasmodics, laxatives, rifaximin, and bile acid sequestrants showed no elevated risks.

Dr. Ali Rezaie Leads Groundbreaking Cedars-Sinai Research

Dr. Ali Rezaie, GI Motility Program medical director at Cedars-Sinai, served as senior author. The team published findings April 16, 2026, in Communications Medicine. Rezaie stated IBS patients should not panic but must understand small yet meaningful long-term risks before committing to treatments. He called for more research to pinpoint mechanisms and high-risk groups. This real-world data from objective health records provides unprecedented scale and reliability.

Researchers stress associations do not prove causation. Patients on these drugs experienced more cardiovascular events, falls, strokes, and injuries. Those with severe IBS or comorbidities likely receive these prescriptions, confounding results. Individual absolute risks stay low despite statistical significance. Conservative principles demand personal responsibility: patients and doctors must prioritize informed consent over quick symptom fixes.

Immediate Clinical and Patient Impacts Unfold

Physicians now reconsider long-term prescribing of antidepressants and antidiarrheals for IBS. Patients on these drugs face new anxiety, though experts emphasize short-term benefits often outweigh risks. Media coverage amplifies awareness, pushing shared decision-making. Elderly IBS sufferers appear especially vulnerable to falls and heart complications. Millions affected, as 10-15% of Americans have IBS.

Common IBS medications linked to higher risk of death in major study

A massive, nearly 20-year study tracking over 650,000 Americans with irritable bowel syndrome is raising new questions about the long-term safety of common treatments. Researchers found that some widely used…

— The Something Guy 🇿🇦 (@thesomethingguy) April 16, 2026

Long-term, FDA may review safety profiles for these classes in IBS. Professional groups could revise guidelines favoring safer options like antispasmodics. Drug developers gain incentive for better alternatives. Post-market surveillance improves for chronic meds. Common sense aligns with facts: over-reliance on off-label antidepressants ignores unproven benefits against proven associations. Patient autonomy strengthens through transparency.